These SEO-friendly content writing tips can help security industry professionals enhance their online visibility, attract more visitors and outperform their competition.

Here are actionable tips and strategies for crafting compelling copy that attracts and converts clients in the ever-competitive security industry.

In this comprehensive white paper, J. J. Keller’s subject matter experts provide answers to the most frequently asked questions about safety plans and share essential steps for successful implementation.

Washington — Facilities that produce or handle hazardous chemicals should prepare written procedures and establish policies for evaluating simultaneous operations to ensure “robust safe work practices,” the Chemical Safety Board says.

Using a power tool? Working ergonomically will help prevent injuries to your wrist.

Boston — Intended to give small health care employers an “easy-to-use format” for a written exposure control plan, the Massachusetts Department of Public Health has published sample written plans for a respiratory protection program and bloodborne pathogen exposure control.

Mars Wrigley unveiled several new insight-backed offerings that deliver on shoppers' evolving requests for a wider variety of products. 

Arlington, VA — Mine operators will soon be required to have a written safety program for mobile and powered haulage equipment “developed and updated with input from miners and their representatives.”

Are you holding your trowel at the right angle? Scott Carothers, academic director, Ceramic Tile Education Foundation, challenges tile installers to take another look at the angle at which they are troweling thinset.  

Perhaps you've heard of us, perhaps not. Look at your smartphone, digital camera, smart TV, gaming console, or your saved images in the cloud. Guess what, you’ve already got an Arm-based device or are connected to one!

Get a buzz out of learning new technologies? Do you enjoy writing? Arm’s Information Developers and Technical writers work with exciting and results-oriented projects that really impact the technological world. The fresh ideas of undergraduates and people early in their careers can help shape these technologies. People at Arm are diverse, dedicated, and innovative. We'd like you to bring your passion and curiosity to our company, and share your ideas! In return, we'll provide training, coaching, and a challenging environment to start your career. You'll be exposed to technologies that will be the foundation for innovative products for years to come! At Arm, we encourage our undergraduates to strengthen their proficiencies while advancing their education. You can build a career as unique as you are, with your team mates and leaders right there supporting you, even when the world throws us curveballs. 

Arm Information Developers and Technical Writers create different types of technical content, including web content, specifications, tutorials, and multimedia. This content helps our customers and ecosystems to design and develop with Arm products and solutions.

Arm has a range of vacancies for enthusiastic undergraduates with ambitions in writing and technology. You will be part of a larger community of writers, who can guide, train, and give suggestions. We nurture our people, we provide one-to-ones, and a collaborative and friendly working environment. Our leaders are open to sharing their career experiences and also giving feedback for your development.

Now you can wear your brutally honest love for architecture on your wrist with the B/1 watch by Toledano & Chan inspired by Marcel Breuer's NYC landmark.

Allee Willis was your favorite artists’ favorite artist decades before Chappell Roan. Allee Willis was a truly fascinating, wildly-creative artist who worked almost exclusively behind the scenes. She was your favorite artists’ favorite artist decades before Chappell Roan. Allee Willis: creative force behind the Friends TV Show Theme, Dangerous Woman to Soviet newspapers Allee Willis: Creative Force, Dangerous Woman, Queer Songwriter Behind Friends' Theme Further Proof That Friends Is Queer-Coded by Melissa Locker

Whether you watched the show or not, you can probably hum the theme song to Friends. Do you know who wrote it for the Rembrandts? And "September"—the Mercury's second favorite song—do you know who co-wrote that with Earth Wind and Fire's Maurice White?

Not to sound like a weird TV pitchman, but what if I told you they were written with the same person. Specifically,  Allee Willis—who was once dubbed “the most dangerous woman in the world” by Pravda, the the official newspaper of the prelapsarian Soviet Union.  

Willis is the star of a new documentary, The World According to Allee Willis, which celebrates its Oregon premiere at the QDoc Film Festival on November 16. The doc is worth your time to burnish your bar trivia skills, but also because Willis was a truly fascinating, wildly-creative artist who worked almost exclusively behind the scenes. She was your favorite artists’ favorite artist decades before Chappell Roan.

Willis had insisted on documenting her life, since 1978, long before reality TV was a thing, so there's plenty of her archival video found in the film. "I've always known that my final art piece would be someone putting together the trail I've left behind," she says in one clip. 

In 2019, Willis died at age 72, and director Alexis Manya Spraic became responsible for following that trail. Spraic intersperses the footage with a cavalcade of famous faces—Paul Reubens, Lily Tomlin, Cyndi Lauper, Pamela Adlon, Paul Feig, Sex and the City director Michael Patrick King, Devo’s Mark Mothersbaugh, as well as—somewhat inexplicably—billionaire Mark Cuban. Their interviews confirm that Willis really was a Hollywood power player, even if you don’t know her name.

Raised in Detroit as Alta Willis, the artist admits that growing up in the shadow of Motown influenced her work. She also did a stint in New York where she wrote her one and only album, Childstar, which had “great reviews and zero sales.” Eventually Willis moved to California because “if she was going to starve to death, she was going to do it in the sun.” ["Not me!" -Portland creatives.]

Willis lived on welfare in that sun, until "Godmother of Soul" Patti LaBelle heard her music, and kickstarted Willis’ songwriting career. Then came Earth Wind & Fire and “September,” the track that made Willis a songwriting star.

"Allee said she was lucky to meet us. We were lucky to meet her, too,” the group's bassist Verdine White says in the film. “That was life-changing for all of us.”

Earth Wind & Fire followed the success of "September" by co-writing another hit “Boogie Wonderland” with Willis, helping her become the music industry’s go-to “rock doc” who could fix up a song and turn it into a hit. 

In addition to being a wildly successful songwriter, Willis was also an art director and set designer, creating the backdrops for Debbie Harry music videos, among others. She continued to collaborate on songs, behind the scenes, and won both a Grammy and a Tony for her work on the musical The Color Purple.  The Friends theme was nominated for an Emmy, but didn't win.

While Willis was able to find professional success, that never quite translated into financial solvency. She also faced challenges in her private life—partially because she was queer at a time when it was extremely difficult to be open and out. She struggled with loneliness for much of her life, Lauper says during one of the film's interviews.

Willis did eventually find love, and then had to contend with the near-universal struggle of balancing work, creativity, and her personal life. When you’re looking at The World According to Allee Willis, it's a wild,  wonderful, and sometimes painful view, but well worth watching.

The World According to Allee Willis screens as part of QDoc Film Festival at Hollywood Theatre, 4122 NE Sandy, Sat Nov 16, 4:30 pm, $12, tickets here. Some streaming starting Nov 22. Visit alleewillisdoc.com for more.

In a first-best world, we'd all save enough money and there'd be no scammers. In a second-best world, we'd all know how to protect ourselves.

That's what Sheila Bair thought, too. As former chair of the FDIC, she noticed many kids and adults weren't quite getting the education they needed. So, she decided to do something about it.

Today on the show: What Sheila Bair has learned about American capitalism as one of its top regulators and how she's trying — one book at a time — to help new generations from falling into its traps.

We learned about Sheila Bair's kids books from listener Erin Vetter. If you've come across anything that makes finance fun, email us! We're at indicator@npr.org.

Related Episodes:
Mailbag: Children Edition
Beach reads with a side of economics

For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org.

Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter.

This week marked the launch of the second annual edition of The People's Book, a collection of literary works and visual art created by New Hampshire writers and artists.

The Exchange presents a special broadcast of Writers on a New England Stage with Kevin Kwan. Host Peter Biello talks with the author of the bestselling Crazy Rich Asians about his new book Sex and Vanity.

The Exchange presents a special broadcast of Writers on a New England Stage with Rebecca Carroll. Carroll is an award-winning author, podcast host and Black culture critic.

The Exchange presents a special broadcast of Writers on a New England Stage with Diane Rehm.

The Exchange presents a special broadcast of Writers on a New England Stage with economist and New York Times columnist Paul Krugman.

The Exchange presents a special broadcast of Writers on a New England Stage with environmental activist Erin Brockovich.

The Exchange presents a special broadcast of Writers on a New England Stage with Kevin Kwan. Host Peter Biello talks with the author of the bestselling Crazy Rich Asians about his latest book, Sex and Vanity.

NHPR and The Music Hall in Portsmouth present Writers on a New England Stage with i nternational bestselling author and podcast host Malcolm Gladwell, who sat down with Peter Biello to discuss his new book, Talking to Strangers: What We Should Know About the People We Don’t Know .

'In Maine, when we say something is "wicked good" – we really mean it.' That's how LL Bean describes their Wicked Good Slippers, and how we describe Jeff Ryan, who for decades wrote Bean's catalog copy. We spoke to him about finding the story in everyday objects and the tricks of the trade when it comes to copy writing. Jeff Ryan is also the author of Appalachian Odyssey, a memoir of hiking the Appalachian Trail, bit by bit, over 28 years. Episode music: "Auld Lang Syne" by Podington Bear Credit music: "Joy in the Restaurant" by David Szesztay Learn more about your ad choices. Visit podcastchoices.com/adchoices

“Truth is the first casualty of war!” It’s a good line. Not mine. That belongs to George Orwell in the 1940s…or perhaps Arthur Ponsonby in 1928…or maybe United States Senator Hiram Johnson in 1918…or probably Samuel Johnson in 1758…or possibly, as with most things, Aeschylus in 500 B.C. Actually, no one is aware of the origin as even with first documented uses it is referenced as “an ancient proverb”.

Cosmonaut candidate Andrei Babkin, who was dismissed from his flight position in September due to a runny nose, wrote a letter to Russian President Vladimir Putin. In his address to the head of state, Babkin wrote that he would like independent experts to assess his health condition. In response, the Roscosmos Cosmonaut Training Center (CTC) said that an extended consultation was held on July 12. Members of the ENT section of the Main Medical Commission, as well as specialists who had previously treated the cosmonaut, were present at the meeting. As a result, no grounds were found for revising the previous medical conclusion in relation to the cosmonaut candidate.

[Culture] :
Korean American writer Kim Ju-hea was named the winner of the 2024 Yasnaya Polyana Literary Award in the foreign fiction category for her debut novel, "Beasts of a Little Land." Kim and Kirill Batygin, who translated the book into Russian, were awarded Russia's largest annual prize in literature at Moscow's ...

[more...]

[Culture] :
The Writers Association of Korea says Han Kang’s recognition with a Nobel Prize in Literature is a blessing for literary language. The association, one of the nation’s most prominent writers’ groups, said in a statement Friday that the latest feat is a reminder of the role that literature plays in ...

[more...]

[Culture] :
Nobel Prize-winning author Han Kang hopes to write three more books over the next six years. Han made the remarks Thursday as she accepted the Pony Chung Innovation Prize at an award ceremony organized by the Pony Chung Foundation. The 53-year-old author, who turns 54 next month, said ages 50 to 60 are ...

[more...]

G-Dragon has helped write a song for Babymonster’s upcoming full-length album which will drop next month. The rookie girl group’s first full-length album “Drip” will drop...

[more...]

Join us on this week’s episode of Good Vibes Only as we sit down with the brilliant Anton Hur—renowned translator, novelist, and literary judge. Discover how he manages to publish as many...

[more...]

Former LA Times food writer Russ Parsons offers John Rabe a piece of pie, in John's Mercedes; Credit: John Rabe/KPCC

Semi-retired, former LA Times food writer Russ Parsons appeared often on Off-Ramp over the years, helping to explain the city’s communities through their food, as well as giving solid cooking advice. For the final edition of Off-Ramp, John picked up Russ at Jongewaard's Bake-N-Broil, a Long Beach institution.

Parsons brought John an olallieberry pie (a cross of 'Black Logan' blackberries and youngberries), whilst the inimitable Parsons -- author of "How to Pick a Peach: The Search for Flavor from Farm to Table" and "How to Read a French Fry: And Other Stories of Intriguing Kitchen Science" -- opted for the coconut cream.

Listen to the audio for John and Russ' observations on how food brings the disparate cultures of Los Angeles together, and to hear about which part of hosting Off-Ramp is as humbling for John as it is for Parsons when readers tell him they cook his food at Thanksgiving.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Edgar Wright attends the 55th Annual International Cinematographers Guild Publicists Awards at The Beverly Hilton Hotel on March 2, 2018 in Beverly Hills, California.; Credit: Tommaso Boddi/Getty Images

The joke about Sparks — if you’ve even heard of them — is that it’s the best British band to come out of America. That confusion is why Edgar Wright, the director of “Baby Driver” and “Shaun of the Dead,” wanted to make his first documentary about the group, headed by brothers Ron and Russell Mael. Quite simply, Wright was tired of explaining who the band was and why he loves them. His documentary, called “The Sparks Brothers,” premiered at this year’s Sundance Film Festival. John Horn talked with Wright after its January premiere about his personal connection to the band, how he connected with the brother, the editing process of the documentary and more. The film is in theaters now.

With guest host John Horn

Guest: 

Edgar Wright, director of the new documentary “The Sparks Brothers;” he tweets @edgarwright

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Ed Arce 10/09/2024

H.C. Wainwright & Co. analysts Ed Arce and Thomas Yip, in a research report published on October 9, 2024, maintained a Buy rating on Unicycive Therapeutics Inc. (UNCY:NASDAQ) with a price target of US$2.50. The report follows Unicycive's announcement of the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.

Arce and Yip highlighted the significance of the study results, stating, "UNI-494 showed rapid metabolism, enabling the expected release of nicorandil and its linker." They added, "Importantly, PK results collected in the study showed fast absorption of UNI-494, with rapid metabolism leading to the expected release of nicorandil and its linker."

The analysts noted the safety profile of UNI-494, commenting, "UNI-494 was generally safe and well-tolerated; headache was the most common adverse event (AE), and all AEs were mild with no serious adverse events (SAEs) or AEs leading to withdrawal in Part 1."

Regarding Unicycive's strategic plans, the analysts stated, "Management plans to request a meeting with the FDA by year-end 2024 to review these Phase 1 results and discuss the design of a potential Phase 2 study in patients with acute kidney injury (AKI)."

The report also highlighted the pending milestone for Unicycive's other product candidate, Oxylanthanum Carbonate (OLC), noting, "We await the FDA's formal acceptance of the NDA for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis (we expect by November 2) with a PDUFA date assignment to further narrow OLC's potential approval timing."

H.C. Wainwright & Co.'s valuation methodology for Unicycive is based on a risk-adjusted Net Present Value (rNPV) model. The analysts explained, "We employ a rNPV valuation model to estimate the value of UNCY shares and arrive at our US$2.50 PT based on: (1) about US$2.30 per share for royalties on net sales of OLC in the U.S. and EU (85% PoS, US$149.1M global peak revenue in 2034); and (2) about US$0.25 per share for royalties on net sales of UNI-494 in the U.S. and EU for AKI (20% PoS; US$195M global peak revenue in 2036)."

They added, "In our valuation model, we employ a 14.5% discount rate, which we believe adequately reflects the overall risks of the Unicycive development pipeline. We conservatively assume zero terminal value after the end of the market exclusivity period that runs through 2037."

The analysts also outlined several risk factors, including regulatory, commercialization, market, intellectual property, and funding risks.

In conclusion, H.C. Wainwright & Co.'s maintenance of a Buy rating and US$2.50 price target reflects a positive outlook on Unicycive Therapeutics' potential in developing UNI-494 for AKI and OLC for hyperphosphatemia. The share price at the time of the report of US$0.36 represents a potential return of approximately 594% to the analysts' target price, highlighting the upside potential if the company's clinical development and regulatory plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Unicycive Therapeutics Inc., October 9, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Ed Arce and Thomas Yip , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Unicycive Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Unicycive Therapeutics, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Unicycive Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Unicycive Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: UNCY:NASDAQ, )

Source: Andrew Fein 10/23/2024

H.C. Wainwright & Co. analysts Andrew S. Fein, Matthew Caufield, Dr. Andres Y. Maldonado, and Dr. Ananda Ghosh, in a research report published on October 23, 2024, maintained a Buy rating on DBV Technologies SA (DBVT:NASDAQ) while raising their price target to US$7.00 from US$5.00. The report follows DBV's announcement of regulatory clarity regarding the path forward for its Viaskin Peanut patch.

The analysts highlighted the significance of the FDA agreement, stating, "DBV Technologies has reached an agreement with the FDA regarding the regulatory pathway for the Viaskin Peanut patch in toddlers aged one to three, under the Accelerated Approval pathway."

Regarding the company's development timeline, the analysts noted, "The Biologics License Application (BLA) submission for Viaskin Peanut in this age group is expected to be supported by positive efficacy and safety data from DBV's completed EPITOPE Phase 3 study, as well as additional safety data from the upcoming six-month COMFORT Toddlers supplemental safety study, which is expected to begin in 2Q25."

The report emphasized the strength of DBV's regulatory position, stating, "The FDA has stated that DBV has already satisfied two of the three criteria: the product treats a serious condition, and the product candidate provides a meaningful advantage over available therapies."

The analysts also highlighted progress in Europe, noting, "The EMA confirmed that the successfully completed EPITOPE Phase 3 efficacy and safety trial in the one to three-year-old population, along with positive results from the VITESSE study in the four to seven-year-old population, and a new safety study using the modified circular patch in one to three-year-olds, could support an MAA for the one to seven-year-old indication with the modified patch."

The analysts' valuation methodology for DBV Technologies is based on a composite approach. They explained, "Our US$7 price target is based on an equally weighted composite of: (a) US$5.10/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of US$5.13 discounted back to FY24 at 35%; and (b) an NPV of US$8.52/share with a 13% discount rate and 1% growth rate."

The report included commercial projections, with the analysts stating, "We continue to model initial approval in 2027, with projected initial sales of US$17.5M, growing to US$1,182.8M by 2034."

The analysts also outlined several risk factors, including potential clinical study failures, regulatory approval challenges, and market size uncertainties.

In conclusion, H.C. Wainwright & Co.'s increased price target to US$7 reflects growing confidence in DBV Technologies' regulatory pathway for the Viaskin Peanut patch. The share price at the time of the report of US$0.70 represents a potential return of approximately 900% to the analysts' target price, highlighting the significant upside potential if the company successfully navigates the regulatory process and commercializes its product.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co. DBV Technologies S.A., October 23, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Andrew S. Fein, Matthew Caufield, Andres Y. Maldonado, PhD and Ananda Ghosh, PhD , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of DBV Technologies S.A. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of DBV Technologies S.A.

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from DBV Technologies S.A. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from DBV Technologies S.A. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in DBV Technologies S.A. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: DBVT:NASDAQ, )

President Barack Obama presents novelist, essayist and screenwriter Larry McMurtry with a National Humanities Medal in September 2015.; Credit: Leigh Vogel/WireImage/Getty Images

Larry McMurtry, a prolific, Pulitzer Prize-winning author and Oscar-winning screenwriter, has died at age 84. He was beloved for riveting and yet unsentimental depictions of the American West in books like Lonesome Dove, as well as for tales of family drama including Terms of Endearment.

In a statement, his representative Amanda Lundberg said McMurtry "passed away last night, on March 25 of heart failure at 84 years old surrounded by his loved ones who he lived with including long time writing partner Diana Ossana, his wife Norma Faye and their 3 dogs."

In all, McMurtry wrote more than 30 novels as well as over a dozen non-fiction works that spanned memoir, history and essays. He also wrote over 20 screenplays and television scripts.

McMurtry was also famous for his bookstore, Booked Up in Archer City, Texas. Even after selling off more than half of his holdings in 2012, he still had about 200,000 books between his private collection and the store.

When he won an Oscar in 2006 for the screenplay adaption of E. Annie Proulx' short story Brokeback Mountain, which he co-wrote with longtime writing partner Diana Ossana, he thanked booksellers.

"From the humblest paperback exchange to the masters of the great bookshops of the world," he said, "all are contributors to the survival of the culture of the book, a wonderful culture, which we mustn't lose."

Filmmakers were drawn to McMurtry's work; his books Hud, The Last Picture Show and Terms of Endearment were all made into films. Lonesome Dove, which earned him the Pulitzer in 1985, became a successful TV miniseries in 1989, starring Robert Duvall and Tommy Lee Jones.

Born in 1936 on a Texas ranch, McMurtry came to his love of the West through his family. His grandfather broke horses, and his father raised cattle.

"The West is mostly a very beautiful place," he told All Things Considered in 2014. "There are all those lovely spaces. There are all those running horses. It's a poetic imagery and it's been there for a long time."

But he wanted to scour that landscape of sentimental nostalgia for cowboys, he added. "To me it was hollow and I think it was hollow for my father, although he might not have ever brought that to his conscious mind. He totally loved cowboys and so did most of the cowboys we worked with and that got him through his life. But he knew perfectly well, so did we, that it wouldn't last another generation, it just was not going to last."

This content is from Southern California Public Radio. View the original story at SCPR.org.

A video created as part of the Transportation Research Board’s centennial celebration has been named the winner of three 2020 Telly Awards, which annually showcase the best work created within television and across all types of video production.

Communities in the Gulf of Mexico are especially familiar with the whims of nature and power of the sea. This year’s hurricane season has already brought power outages, heavy rain, downed trees, and death and injury. Roy Wright talks about the compounding effects and lasting impacts of disasters on shaping resiliency in the Gulf.

By the time you read this, most people’s New Year’s resolutions or goals will be a distant memory, and they’ll be back to doing the same things they said they weren’t going to do. 

The company will produce four new projects over the next two years.

Writing Services Shine

Embracing Originality: JayQ the Legend Champions Creative Expression Amid the AI Era

Dominican-American writer/director from Providence, RI, Vega Montañez, draws the support of undefeated UFC fighters, Hip Hop Icons, Media Personalities, and an Emmy Award winning producer to bring his next feature film to audiences around the world.

After a successful tenure as an optician, Mr. McCrohan has been focusing his career on painting and writing

Carol C. Wright is being recognized for inspiring dedication to nursing and to senior advocacy

Bracket games have become increasingly popular even amongst casual fans. Net Score is a clever way to play alongside the men's division 1 tournament held in March. Let your readers know what's new. Useful links are attached to this release.

Brenton Wright is the founder and CEO of Virely LLC, a Software as a Service marketing technology firm

Karlene Wright, DDS channels years of experience into her work with Aesthetic Family Dentistry of Columbia

Geraldine Mulhall-Wright, DC, FICPA, CACCP, recognized for more than 25 years of success as a chiropractor.

Shabazz Arts will launch a Kickstarter campaign for their new graphic novel, Bearcat Wright & The Kayfable Chronicles. The book tells the story of Wright, the first African American pro-wrestling champion.

Hailing from a full-time career in project management, Apinder Kaur Bedi has found new success as a writer

Alan H. Rosenus is a distinguished expert in Western American writing